Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 267 followers
Latest posts
Last updated 3 days ago
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
3 days ago
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus...
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
5 days ago
In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg...
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
6 days ago
Huntsville site will focus on domestic production of small molecule synthetic and...
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
7 days ago
INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
7 days ago
The risk reduction observed in BRUIN CLL-313 is among the most compelling...
Lilly declares first-quarter 2026 dividend
7 days ago
INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of...
Carolyn Bertozzi returns to Lilly board of directors
8 days ago
INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of...
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
8 days ago
In addition to meeting the primary endpoint of non-inferiority for overall response...
Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers
12 days ago
December 3, 2025 For Release : Immediately Refer to: Carrie Munk; munk_carrie@lilly.com...
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
12 days ago
Approval is based on results from the BRUIN CLL-321 trial, the only...
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials
15 days ago
Lilly continues efforts to expand access for people living with obesity by...
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
21 days ago
Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone...